Colonne 1


Research and development has been at the very heart of Crossject since the company's initial work on its innovative needlefree self-injection system ZENEO® in 1997.

For its R&D, constantly focused on innovation, Crossject has formed a team of about 60 people, recruited from a range of specialties and industries to ensure a variety of missions within the company :

•  determination of patient needs,
•  research on existing molecules,
•  management of regulatory, medical and pharmaceutical affaires,
•  identification of partners and commercial distributors, etc.